Cargando…

1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?

BACKGROUND: Novel therapies for multidrug-resistant TB are needed and new BLIs could answer this call. Mtb encodes for BlaC, a class A β-lactamase. BlaC is inhibited by clavulanate (CLA) while the DBO avibactam (AVI) is an inefficient inhibitor (low k(2)/K value). Carbapenems are hydrolyzed slowly b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, David, Bethel, Christopher, Taracilla, Magdalena A, Li, Qing, Dousa, Khalid M, Kurz, Sebastian G, Nguyen, Liem, Kreiswirth, Barry N, Boom, Wilem, Bonomo, Robert A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643912/ http://dx.doi.org/10.1093/ofid/ofab466.1582

Ejemplares similares

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
por: Shapiro, Adam B., et al.
Publicado: (2021)

Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action
por: Dousa, Khalid M., et al.
Publicado: (2022)

1432. Exploring Cell Wall Targets to Overcome Mycobacterium tuberculosis (Mtb): Ceftriaxone (CRO) Inhibits Ldt(Mt2), a Major Peptidoglycan (PG) Synthase
por: Nguyen, David C, et al.
Publicado: (2022)

Crystal Structure of Phosphoserine BlaC from Mycobacterium tuberculosis Inactivated by Bis(Benzoyl) Phosphate
por: Moural, Timothy W., et al.
Publicado: (2019)

1642. A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)
por: Dousa, Khalid M, et al.
Publicado: (2020)

Fluorogenic Probes with Substitutions at the 2 and 7 Positions of Cephalosporin are Highly BlaC-Specific for Rapid Mycobacterium tuberculosis Detection**
por: Cheng, Yunfeng, et al.
Publicado: (2014)

2806. The Mechanism of β-Lactam Antibiotic Action: Structural Analysis of Mycobacterium abscessus l,d-Transpeptidases, d,d-Carboxypeptidase and penicillin-binding-proteins binding by imipenem, ceftaroline, and amoxicillin
por: Shin, Eunjeong, et al.
Publicado: (2023)

β-Lactamase inhibition profile of new amidine-substituted diazabicyclooctanes
por: Iqbal, Zafar, et al.
Publicado: (2021)

Structure of Ldt(Mt2), an l,d-transpeptidase from Mycobacterium tuberculosis
por: Böth, Dominic, et al.
Publicado: (2013)

Isolation, Purification and Characterization of L,D-transpeptidase 2 from Mycobacterium tuberculosis
por: Baldin, S. M., et al.
Publicado: (2019)

Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes
por: Lang, Pauline A., et al.
Publicado: (2021)

Interactions of the Diazabicyclooctane Serine β-Lactamase Inhibitor ETX1317 with Target Enzymes
por: Shapiro, Adam B., et al.
Publicado: (2020)

Correction to Lancet Infect Dis 2020; 20: 1390–400
Publicado: (2020)

Protective Efficacy of BCG Overexpressing an L,D-Transpeptidase against M. tuberculosis Infection
por: Nolan, Scott T., et al.
Publicado: (2010)

Variations in the SDN Loop of Class A Beta-Lactamases: A Study of the Molecular Mechanism of BlaC (Mycobacterium tuberculosis) to Alter the Stability and Catalytic Activity Towards Antibiotic Resistance of MBIs
por: Bhattacharya, Sourya, et al.
Publicado: (2021)

Dbo/Henji Modulates Synaptic dPAK to Gate Glutamate Receptor Abundance and Postsynaptic Response
por: Wang, Manyu, et al.
Publicado: (2016)

1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy
por: Dousa, Khalid M, et al.
Publicado: (2019)

Targeting the Mycobacterium tuberculosis transpeptidase Ldt(Mt2) with cysteine-reactive inhibitors including ebselen
por: de Munnik, Mariska, et al.
Publicado: (2019)

Hypothyroidism in the “Arnolfini Portrait” (1434) by Jan Van Eyck (1390–1441)
por: Ashrafian, H.
Publicado: (2017)

Comparison of the diagnostic performance of NBI, Laser-BLI and LED-BLI: a randomized controlled noninferiority trial
por: Higurashi, Takuma, et al.
Publicado: (2022)

Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase Ldt(Mt2) by biapenem and tebipenem
por: Bianchet, Mario A., et al.
Publicado: (2017)

Structural Characterization of Diazabicyclooctane β-Lactam “Enhancers” in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa
por: Rajavel, Malligarjunan, et al.
Publicado: (2021)

ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
por: Tew, Ben Yi, et al.
Publicado: (2023)

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
por: Collins, Christopher E, et al.
Publicado: (2006)

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review
por: Principe, Luigi, et al.
Publicado: (2022)

Toward antituberculosis drugs: in silico screening of synthetic compounds against Mycobacterium tuberculosis l,d-transpeptidase 2
por: Billones, Junie B, et al.
Publicado: (2016)

A Fluorescence‐Based Assay for Screening β‐Lactams Targeting the Mycobacterium tuberculosis Transpeptidase Ldt(Mt2)
por: de Munnik, Mariska, et al.
Publicado: (2019)

1390. Assessing the Relationship between Community Social Vulnerability and Antibiotic Use in Nursing Homes
por: Zipfel, Casey M, et al.
Publicado: (2022)

LEP kan bli den sista jattemaskinen
por: Winge, S
Publicado: (1982)

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
por: Durand-Réville, Thomas F., et al.
Publicado: (2020)

The Mycobacterium tuberculosis gene, ldt(Mt2), encodes a non-classical transpeptidase required for virulence and resistance to amoxicillin
por: Gupta, Radhika, et al.
Publicado: (2010)

Activity-Based Protein Profiling Reveals That Cephalosporins Selectively Active on Non-replicating Mycobacterium tuberculosis Bind Multiple Protein Families and Spare Peptidoglycan Transpeptidases
por: Lopez Quezada, Landys, et al.
Publicado: (2020)

The current status of targeting BAFF/BLyS for autoimmune diseases
por: Ramanujam, Meera, et al.
Publicado: (2004)

Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review
por: Granata, Guido, et al.
Publicado: (2022)

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii
por: Moussa, Samir H., et al.
Publicado: (2023)

Whole-genome-sequence-based characterization of an NDM-5-producing uropathogenic Escherichia coli EC1390
por: Thuy, Tran Thi Dieu, et al.
Publicado: (2022)

Draft Genome Sequences of Bradyrhizobium elkanii Strains BLY3-8 and BLY6-1, Which Are Incompatible with Rj(3) Genotype Soybean Cultivars
por: Zaw Htwe, Aung, et al.
Publicado: (2016)

Structural basis for the inhibition of Mycobacterium tuberculosis l,d-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains
por: Kim, Hyoun Sook, et al.
Publicado: (2013)

Crystal structures of the transpeptidase domain of the Mycobacterium tuberculosis penicillin‐binding protein PonA1 reveal potential mechanisms of antibiotic resistance
por: Filippova, Ekaterina V., et al.
Publicado: (2016)

High-throughput screen with the l,d-transpeptidase Ldt(Mt2) of Mycobacterium tuberculosis reveals novel classes of covalently reacting inhibitors
por: de Munnik, Mariska, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a9dvrkn1vla15lpfqbd391ug3p